CXCR4-targeted gemcitabine conjugate extends survival in pancreatic cancer mice

The wire

1. 01Researchers linked a CXCR4 antagonist peptide to gemcitabine, reporting reduced Erk and P38 phosphorylation, less CXCL12-driven tumor cell migration, and longer survival than gemcitabine in orthotopic pancreatic cancer mice.
2. 02The conjugate also cut tumor-associated macrophages and raised CD8+ T-cell infiltration without the peripheral blood count drops that limit gemcitabine dosing.
3. 03Findings are from cell lines and a mouse model only, with no human data, dosing schedule comparisons or toxicology package reported.

From the source

A Dual-Action CXCR4-Targeted Peptide-Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer

Molecular pharmaceutics · 2026 Oct 5 · Zhu K, Liu X, Li D et al.